Free Trial
NASDAQ:PULM

Pulmatrix (PULM) Stock Price, News & Analysis

Pulmatrix logo
$6.36 -0.16 (-2.53%)
As of 05/2/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Pulmatrix Stock (NASDAQ:PULM)

Key Stats

Today's Range
$6.32
$6.52
50-Day Range
$5.39
$8.46
52-Week Range
$1.72
$10.40
Volume
6,778 shs
Average Volume
133,028 shs
Market Capitalization
$23.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

Receive PULM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter.

PULM Stock News Headlines

Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
See More Headlines

PULM Stock Analysis - Frequently Asked Questions

Pulmatrix's stock was trading at $6.98 on January 1st, 2025. Since then, PULM stock has decreased by 8.6% and is now trading at $6.38.
View the best growth stocks for 2025 here
.

Pulmatrix, Inc. (NASDAQ:PULM) announced its quarterly earnings data on Friday, March, 21st. The biotechnology company reported ($0.54) earnings per share for the quarter. Pulmatrix had a negative net margin of 96.51% and a negative trailing twelve-month return on equity of 45.97%.

Shares of Pulmatrix reverse split on the morning of Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Pulmatrix's top institutional investors include SBI Securities Co. Ltd. (1.43%).
View institutional ownership trends
.

Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pulmatrix investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), GE Aerospace (GE), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO) and Adobe (ADBE).

Company Calendar

Last Earnings
3/21/2025
Today
5/03/2025
Next Earnings (Estimated)
5/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PULM
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-14,120,000.00
Pretax Margin
-96.51%

Debt

Sales & Book Value

Annual Sales
$7.81 million
Price / Cash Flow
N/A
Book Value
$4.93 per share
Price / Book
1.29

Miscellaneous

Free Float
3,629,000
Market Cap
$23.29 million
Optionable
Not Optionable
Beta
1.38

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:PULM) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners